Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-BCMA for relapsed/refractory multiple myeloma (Phase II, open-label, single-arm, multicenter)
CTR20230238Phase 2Active
- Sponsor
- Shenzhen Puruijin Biological Pharmaceutical Co., Ltd.
- Start
- Feb 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of CART-BCMA in multiple myeloma (MM), sponsored by Shenzhen Puruijin Biological Pharmaceutical Co., Ltd.. Started Feb 2023; status: active.
02
Drugs
CART-BCMA
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20230238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230238.